Are AMPH insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies AMPH leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Stock Ratings / Health Care / AMPH / insiders

VSTM (36) RAPP (30) SNDX (17) AVLN (44) ⌘ Pro Terminal →

Amphastar Pharmaceuticals Inc. (AMPH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$27.03 -2.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $26.97

Amphastar Pharmaceuticals Inc. (AMPH) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $1.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $27.03 (-2.49% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AMPH ranks #62 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMPH compare to VSTM and RAPP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B (72/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, VSTM (Verastem Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMPH?

▼

Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $26.97 (-0.21%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 16.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMPH)Realized 20D OHLCV Swing Band: ±6.8%

Deterministic 5-Pillar Attribution (72/100 Composite)

🔍 WHY AMPH SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (22% of score)

20D Institutional Volume Accumulation (±6.8% realized swing band)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk11/20 pts (-9 pt drag)

Balance-sheet & 10-K footnote risk deducts 9 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$26.05-0.4% Next Q

Q2 (-2Q)

Grade B-$25.94-1.4% Next Q

Q3 (-1Q)

Grade B-$25.57+5.7% Next Q

Current

Grade B$27.03+7% Hist 90D α

Trajectory: C+ (64) → B (72)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AMPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, AMPH faces multiple-compression risk if 11.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 47.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($25.00) or 200D SMA ($22.26) invalidates the momentum regime and cuts Target Base ($28.73) toward Bear Floor ($22.16).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 72%NO 28%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

AMPH Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (AMPH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on AMPH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (AMPH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.87%▲ ASCENDING CHANNEL

2026-11-03O $26.93H $27.72L $26.93C $27.03VOL 664.5K

RES: $30.12SUP: $25.29SMA50: $25.00SMA200: $22.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMPH Butterfly Map → + Track AMPH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

2.0%/yr Implied 5Y Growth

vs. -1.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMPH)

Health Care Rank #62 of 1016 ⚔️ VSTM vs AMPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMPH vs. VSTM, RAPP, SNDX, AVLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amphastar Pharmaceuticals Inc. (AMPH) ranks #62 by composite RQD confidence (72/100, grade B) and #336 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMPH ACTIVE Amphastar Pharmaceuticals Inc.	B	72/100	11.7x	49.5%	9.0%	-2.49%	$1.18B	Benchmark Subject
VSTM Verastem Inc.	D-	36/100	—	—	-35.0%	-1.64%	$1.18B	/vstm-vs-amph →
RAPP Rapport Therapeutics Inc.	E	30/100	—	—	-22.9%	+0.32%	$1.20B	/rapp-vs-amph →
SNDX Syndax Pharmaceuticals Inc.	E	17/100	—	—	-35.0%	-4.03%	$1.22B	/sndx-vs-amph →
AVLN Avalyn Pharma Inc.	D	44/100	—	—	—	-0.12%	$1.14B	/avln-vs-amph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001297184

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported GAAP revenue of $719.9M (-1.7% vs. FY2024 revenue of $732.0M , and +11.7% cumulative change since FY2023) , GAAP net income of $98.1M, operating cash flow of $156.1M, and free cash flow of $121.2M (-29.7% YoY). On the balance sheet, AMPH closed FY2025 with $1.63B in total assets against $619.7M in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$719.9M	$98.1M	$156.1M	$121.2M	$1.63B	$619.7M
FY2024 (FY)	2024-12-31	$732.0M	$159.5M	$213.4M	$172.3M	$1.58B	$613.5M
FY2023 (FY)	2023-12-31	$644.4M	$137.5M	$183.5M	$183.5M	—	—

3. AMPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AMPH compare to VSTM and RAPP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AMPH?

Where is AMPH trading relative to its 50-day, 200-day, and 52-week technical levels?

AMPH last traded at $27.03 (-2.49% on volume of 497,733 shares), positioning the stock +8.12% above its 50-day simple moving average ($25.00) and +21.43% above its 200-day simple moving average ($22.26). Across its 52-week range of $16.65 to $29.52, AMPH sits at the 80.7% percentile with a 14-day RSI of 63.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($25.19 to $28.87).

Direct Sub-Reports: AMPH RQD Cockpit AMPH 12M Forecast AMPH Earnings & Move AMPH Dividends & DRIP AMPH Insiders & 13F AMPH Whale Options AMPH Profit Sankey AMPH News & Why

ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

AMPH — Amphastar Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Amphastar Pharmaceuticals Inc. (AMPH) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $27.03 (-2.49% 1D, market capitalization $1.18B).

Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 9.0%, gross margin of 49.5%, operating margin of 19.5%, and free cash flow yield of 10.58%.
Whale 13F & Options Flow (16/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (15/20) + Forensic Balance Sheet (17/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.47, Piotroski F-Score of 7/9, and Debt/Equity of 0.79x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Amphastar Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations..1B. Per the market data, gross margin is 49.5%, operating margin 19.5%, and net margin 13.6%. — for: specific product lines, customer segments, or the detailed revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported $719.9M in annual revenue (up from $732.0M in FY2024, -1.7% YoY) and $98.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($644.4M revenue, $137.5M net income) through FY2025, AMPH scaled operating cash flow to $156.1M and free cash flow to $121.2M, backed by $1.63B in total assets against $619.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 72/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $16.65 – $29.52 52-week range.
🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 11.7x trailing P/E and 9.4x EV/EBITDA against 19.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. A prospective investor should note that the absence of mapped links means no supply-chain ripple analysis is supported by this dataset.

Key Question #1: Can AMPH sustain or expand its 19.5% operating margin and 9.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $719.9M and free cash flow of $121.2M, how will capital allocation balance growth reinvestment against $619.7M in total debt?
Key Question #3: How sensitive is AMPH's 10.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AMPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amphastar Pharmaceuticals Inc. (AMPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMPH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 20h ago

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Yahoo Finance report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock Now Rated "Reduce" by Wall Street Analysts

MarketBeat report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

1 Safe-and-Steady Stock to Research Further and 2 Facing Challenges

The Globe and Mail report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH StockStory • 1d ago

3 value stocks that fall short

StockStory report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Amphastar Pharmaceuticals, Inc. $AMPH Stock: Bridge City Capital LLC Boosts Position

MarketBeat report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Yahoo Finance report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 3d ago

3 profitable stocks with warning signs

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMPH Bull vs. Bear Conversation Board — What's Your Call at $27.03?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMPH 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $36.59 (+32.0%)

📌 Pinned Debate

A 10.58% FCF yield and 10.9x forward P/E sit alongside an insider-conviction pillar score of 17/20, suggesting cash generation is price

Long AMPH at $27.72 targeting $36.59. A 10.58% FCF yield and 10.9x forward P/E sit alongside an insider-conviction pillar score of 17/20, suggesting cash generation is priced cheaply relative to its stated cash flow.. Institutional whale score is 16/20 and the risk/reward vs. the $16.65 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — AMPH's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $23.84 (-14.0%)

Spot @ $27.72

Revenue, net income, and FCF all declined from FY 2024 to FY 2025 while debt rose to $619.7M, and the forensic balance sheet pillar sco

Fading this rally in AMPH at $27.72. Revenue, net income, and FCF all declined from FY 2024 to FY 2025 while debt rose to $619.7M, and the forensic balance sheet pillar scored lowest at 11/20.. With a beta of 1.0 and the stock sitting at $27.72 (52-wk range $16.65–$29.52), the easy multiple expansion is already priced in.